The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Open accessAbstract
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cardiovascular disease (CVD) remains a significant threat to people with obesity and type 2 diabetes (T2D), with a two to three times higher incidence compared to people without diabetes or obesity [1, 2].”
From Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Research works printed but not linked: 2
- Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. · DOI · Paper page
- Disease C, Management R. Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103-s123.
Cited by
Sorted by citations
Items 201–300 of 472
Fan, Y., Wu, L., Zhang, Y., Hu, Q., Mei, J., Prabahar, K., Hernández‐Wolters, B., Kord‐Varkaneh, H., Lei, C., & Zheng, S. J. (2025) · Phytotherapy Research · doi:10.1002/ptr.70071 · Cited by 2
Çakmak, R., Tosun, İ., Avcu, H., Birer, G. C., Akgül, Ö., Saini, K. S., Carnell, J., & Kutlu, O. (2025) · Digital Health · doi:10.1177/20552076251376260 · Cited by 2
Mantovani, M., Kwiendacz, H., Irlik, K., Bucci, T., Hendel, M., Lam, S. H. M., Huang, B., Szromek‐Białek, P., Niezgoda, M., Alam, U., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70136 · Cited by 2
Qin, Y., Liao, L., Qingyun, C., Huang, Y., & Lin, F. (2025) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70117 · Cited by 2
Panfoli, I., & Carlini, L. (2025) · Life · doi:10.3390/life15111718 · Cited by 2
“Therefore, in clinical practice, glucose-lowering, lipid-lowering drugs, and antiplatelet agents are employed [13,14].”
Ahmad, O., Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Elbenawi, H., Salih, M., Farina, J., Bhakta, M. D., Sell‐Dottin, K. A., Yang, E. H., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134042 · Cited by 2
Zhou, X., Zou, C., Li, X., Tian, H., Miao, Y., Ke, T., & Zhao, L. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1712899 · Cited by 2
Kang, Y., Dillon, K. N., Levitt, D. E., & Figueroa, A. (2025) · Nutrients · doi:10.3390/nu17233739 · Cited by 2
Unraveling genetic and epigenetic interplay in type 2 diabetes mellitus and cardiovascular risk
Rehman, M. F. U., Ahmad, N., & Khan, M. M. (2025) · Discover Medicine · doi:10.1007/s44337-025-00556-7 · Cited by 2
The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy
Kanki, M., & Young, M. J. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.01.004 · Cited by 3
Zhou, X., Ruan, W., Pu, J., Zhang, J., Pang, C., Luo, S., & Li, J. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113107 · Cited by 3
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Zhang, S., Fan, S., Wang, H., Li, L., 蘇楷涵, Yin, L., Li, H., Wang, J., & Wang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1731466 · Cited by 2
Janssen, J. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052150 · Cited by 2
“Type 2 diabetes causes excessive cardiovascular morbidity and premature cardiovascular mortality worldwide [110].”
Zhao, Y., Wang, H., Gu, J., Sun, Y., & Zhang, B. (2026) · BioMedical Engineering OnLine · doi:10.1186/s12938-026-01539-0 · Cited by 2
Diabetes and metabolic disorders: Early identification and monitoring strategies
Goyat, J., Tiwari, B. K., & Sharma, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33263-0.00001-2 · Cited by 2
Ramadan, A. (2022) · Sohag Medical Journal · doi:10.21608/smj.2022.131430.1315 · Cited by 2
“Insulin resistance associated with metabolic syndrome triples the risk of coronary artery disease, myocardial infarction, stroke, and cardiovascular death (21) .”
BackgroundChen, J., Zhang, W.-C., Tang, X., Yin, R., Wang, T., Wei, X., & Pan, C. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i1.34 · Cited by 2
Cojić, M., Klisic, A. N., Sahmanovic, A., Petrovic, N., & Kocic, G. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-56451-1 · Cited by 3
Izraiq, M., Al-Mousa, E. N., Hammoudeh, S., Sudqi, M., Ahmed, Y. B., Abu-Dhaim, O. A., Sabbagh, A.-L. M., Khraim, K. I., Toubasi, A. A., Al-Kasasbeh, A., et al. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s465169 · Cited by 2
Effect of Hypoglycemia and Rebound Hyperglycemia on Proteomic Cardiovascular Risk Biomarkers
Nandakumar, M., Sathyapalan, T., Atkin, S. L., & Butler, A. E. (2024) · Biomedicines · doi:10.3390/biomedicines12061137 · Cited by 2
“An increased risk of cardiovascular disease is associated with type 2 diabetes [1], and the United Kingdom Prospective Diabetes Study (UKPDS) suggested that tight glycemic control reduced macrovascular complications [2], though subsequent studies did not [3–5].”
BackgroundMusakaev, D. A., Shaikhalov, M. A., Asvarova, D. G., Bagandalieva, A. M., Pomortsev, N. A., Ayubova, A. S., Rasulova, D. R., & Bolatova, E. Y. (2024) · Archives of Pharmacy Practice · doi:10.51847/qj30frczgf · Cited by 2
Impact of Yoga beyond Physical Training on the Cardiovascular System: An Updated Review
Verma, S., Hatwal, J., & Batta, A. (2024) · The Journal of Tehran University Heart Center · doi:10.18502/jthc.v19i2.16195 · Cited by 2
“46 The atherosclerotic cardiovascular disease (ASCVD) risk score, which includes DM as a risk factor, is used to calculate the 10-year ASCVD risk.”
Prediksi Prevalensi Diabetes Tipe 2 menggunakan Artificial Neural Network
Fernanda, J. W., Bisono, E. F., Nurkhalim, R. F., & Jayanti, K. D. (2024) · Jurnal Sains Matematika dan Statistika · doi:10.24014/jsms.v10i2.26622 · Cited by 2
Batmunkh, N., Enkhtugs, K., Munkhbat, K., Davaakhuu, N., Enebish, O., Dangaa, B., Luvsansambuu, T., Togtmol, M., Bayartsogt, B., Batsukh, K., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195866 · Cited by 2
“While numerous studies have explored the cardiovascular implications of diabetes [1,2,7], fewer have focused on the distinct roles that pre-diabetic conditions, such as IFG, play in driving cardiovascular risk [8,9].”
BackgroundHighly sensitive detection of DNA methyltransferase1 triggered by methylation protection
He, M., Chen, Y., Yin, F., Cheng, W., Wang, Z., & Xiang, Y. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136728 · Cited by 2
Sulangi, A. J., Lyons, S. E., Abdou, A. A., Patel, H., Nagliya, D., Joseph, E., Joseph, C., Kumar, D., Patel, S. S., Jinwala, I., et al. (2024) · Cureus · doi:10.7759/cureus.72648 · Cited by 4
Lee, H., Shin, J., & Choi, J. W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1493663 · Cited by 2
Xin, H. (2024) · American Journal of Translational Research · doi:10.62347/nbkn4311 · Cited by 2
Leonel, L. D. S., Wolin, I. A. V., Danielevicz, A., Diesel, M., Constantini, M. I., de Oliveira, J. B., Souza, A. A., Reichert, T. L., Silveira-Rodrigues, J. G., Soares, D. D., et al. (2025) · Trials · doi:10.1186/s13063-024-08660-2 · Cited by 3
“Additionally, hyperglycemia is associated with dyslipidemia [6], systemic arterial hypertension [7], impairments in muscle strength and functional mobility [8], as well as cognitive dysfunction [9], depression, anxiety [9, 10], and poor sleep quality [11].”
Amini‐Salehi, E., Hasanpour, M., Alotaibi, A. S., Rashidian, P., Hashemi, S. M. H., Nasrollahizadeh, A., Letafatkar, N., Saberian, P., Amani‐Beni, R., & Shanbehzadeh, N. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003089 · Cited by 3
“Review disability in patients with T2DM [ 18–20 ] .”
Arroyo, M. M., Gallegos, I. R., Paublini, H., López-González, Á., López, P. T. T., Sánchez, C. M., Sastre-Alzamora, T., & Ramírez-Manent, J. I. (2025) · Medicina · doi:10.3390/medicina61040613 · Cited by 2
“Hyperglycemia, dyslipidemia, and hypertension contribute to atherosclerosis [29], making cardiovascular diseases the leading cause of mortality in type 2 diabetes [30].”
Leonardo, J., Hertanto, R., Surya, R., Syahputra, R. A., Humayrah, W., Sabrina, N., Taslim, N. A., Tallei, T. E., Tjandrawinata, R. R., & Nurkolis, F. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1571473 · Cited by 2
Shestakova, M. V., Kharakhulakh, M. I., & Belolipetsky, Y. A. (2025) · Diabetes Mellitus · doi:10.14341/dm13238 · Cited by 4
Zhou, M., Zhang, X., Guo, X., Duan, J., Zhang, H., Liu, X., Liu, T., Chen, K., & Liu, C. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04849-8 · Cited by 2
“The incidence rate of cardiovascular disease among individuals with DM is two to three times higher than that observed in non-diabetic individuals [22].”
Agvall, B., & Jonasson, J. M. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-096633 · Cited by 2
Yue, J., Luo, L., Guo, M., & Xu, C. (2025) · Expert Systems with Applications · doi:10.1016/j.eswa.2025.128816 · Cited by 3
Tan, Y., Zhang, Y., Cai, Q., Zhao, R., Luo, W., Jiang, J., Shi, J., Liu, T., Li, Q., & Wang, J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02843-0 · Cited by 2
“It contributes to subclinical structural and functional cardiac abnormalities and is independently linked to increased cardiovascular mortality [3, 4].”
Wudu, M. A., Birhanu, T. A., Tegegne, K. D., & Wondifraw, E. B. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02006-y · Cited by 2
Wang, X., Wu, X., Ouyang, Q., Liu, F., Liu, S., Qiu, J., Zhang, D., He, W., Tian, Q., Li, B., et al. (2025) · Industrial Crops and Products · doi:10.1016/j.indcrop.2025.122170 · Cited by 2
Self-citationШвед, М. І., Yastremska, I. O., & Овсійчук, Р. М. (2023) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2022.v.i4.13496 · Cited by 2
Virginia, D. M., Patramurti, C., Hendra, P., Lorenza, P. N. F. P., Ngai, F. E., Anastasia, N., Defi, M. N., Wahyuningsih, M. S. H., & Nugrahaningsih, D. A. A. (2023) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres22.1541_11.2.255 · Cited by 2
Cao, J., Keyvanshokooh, E., & Liu, T. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4583667 · Cited by 2
Tarif, B. S., & Alhillawi, Z. H. (2023) · Acta Chemica Iasi · doi:10.47743/achi-2023-1-0006 · Cited by 1
“Along with this, the liver also produced more VLDL and TG, two substances that may help T2DM patients develop atherosclerosis and CVD.37 Also, researchers have looked at how insulin inactivity caused by obesity causes an increase in lipid profiles and a major impact on HbA1c levels.38 Xanthine oxidase and Uric acid Th…”
BackgroundInfluentialSarfraz, M., Ullah, H., Iqbal, R., Shaheen, G., Albalawi, M. A., Alatawi, F. S., Omran, A., Areefy, A. A. A., Abdulsalam, N. M., Khateeb, N. A., et al. (2023) · Journal of Animal and Feed Sciences · doi:10.22358/jafs/168793/2023 · Cited by 1
“Combining these natural ingredients could potentially enhance their individual anti-diabetic effects through synergistic interactions (Sarfraz et al., 2016; Ma et al., 2022).”
BackgroundKim, J.-H., Lee, Y., Nam, C. M., Kwon, Y., & Lee, J. (2024) · Endocrine · doi:10.1007/s12020-024-03876-3 · Cited by 1
“Elevated blood glucose levels not only increase the risk of DM but also of cardiovascular diseases (CVDs) [10].”
Abdelazem, A. S., Gaber, O. A., Hussein, S., Nasr, F. M. E., el-Shorbagy, E., Ibrahim, S. M., Abdel-hameed, A. M., Rashad, M. H., El‐Shal, A. S., & Abdelnabi, A.-S. M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10035-4 · Cited by 1
Pataki, J., & Szöllösi, G. J. (2024) · Medicina · doi:10.3390/medicina60121928 · Cited by 2
Serum Cortisol and Cardiovascular Disease Risk - A Potential Biomarker
Oo, W. J., Lim, C. L., Goh, M. H., & Koh, R. Y. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x328499241106064553 · Cited by 1
“A meta-analysis comprising studies from a 10-year span (2007 - 2017) showed a 32% CVD prevalence in patients with type 2 diabetes mellitus (T2DM), whereas a 2 - 3-fold greater incidence was found in T2DM patients worldwide [40, 41].”
Qin, D., Liu, G., Zhang, J., Lin, S., Liu, X., Zhao, J., Zhang, Q., Ma, M., & Wang, S. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s506870 · Cited by 1
“4 While pharmacotherapy effectively reduces glycated hemoglobin (HbA1c) in patients with T2DM, 5 this approach is often associated with adverse effects, 6 increased financial burden, 7 and a diminished quality of life.”
Rong, Y., We, L., Li, K., Guo, J., & Li, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01714-8 · Cited by 1
The Erythrocyte–ROS Axis in Thrombosis and Hemostasis
Borghi, S., Nencini, F., Giurranna, E., Fiorillo, C., & Becatti, M. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2615-0136 · Cited by 1
“25,133,135”
Shen, Z., & Ou, H. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70090 · Cited by 1
“Secondary prevention of cardiorenal complications in these patients requires stringent glycemic control, lifestyle modi fi cations, and medications that reduce cardiovascular risk 3 .”
Factors Associated with the Utilization of Out-of-Region Medical Institutions for Brain Diseases
Go, K.-O., Kim, M.-J., Hwang, K., Seo, S., & Sung, J. H. (2025) · Yonsei Medical Journal · doi:10.3349/ymj.2024.0510 · Cited by 1
“27,28 Cerebrovascular disease often requires more urgent treat-ment than tumors or other brain diseases.”
Histidine‐Containing Dipeptides in Obesity and Cardiometabolic Health: A Systematic Scoping Review
Saadati, S., Kabthymer, R. H., Aldini, G., Thrimawithana, T. R., Stevens, J. E., Ngyuen, K., Majid, A., Bell, S., Feehan, J., Mousa, A., et al. (2025) · Obesity Reviews · doi:10.1111/obr.13965 · Cited by 1
Hao, X. (2025) · American Journal of Translational Research · doi:10.62347/ynwl3428 · Cited by 1
Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus
Sethi, B. K., Chowdhury, S., Jain, S. M., Zargar, A. H., Chadha, M. D., Bhattacharyya, A., Shaikh, S. S., Makkar, B. M., Chawla, M. S., Kalra, P., et al. (2025) · Cureus · doi:10.7759/cureus.87002 · Cited by 1
“These complications are responsible for mortality in at least 50% of patients with T2D [69].”
Shi, S., Sun, X., Sheng, J., Ma, X., Zhao, H., Gao, G., & Ji, B. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s510884 · Cited by 1
Self-citationZhang, Z., Zhang, X., Yang, L., Nie, Q., & Song, G. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s535103 · Cited by 1
Su, I.-M., Teng, Y.-Y., Li, J.-C., Liu, C., Wu, D.-A., & Hsu, B. (2025) · Medicina · doi:10.3390/medicina61091607 · Cited by 1
Shoura, N. K., Elbatreek, M. H., Mousa, M. M., El‐Bassossy, H. M., & El-Azzazy, O. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-19271-5 · Cited by 1
Bhamri, N., Kumar, A., Mishra, C., Devarbhavi, P., Prasad, S., Rudach, D. S., Potdar, A., Patil, S. N., Tewari, A. K., Jagdish, P. S., et al. (2025) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000330 · Cited by 1
Tang, D., Gu, X., Xuan, Y., Zhu, F., Shen, Y., & Lu, L. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/4898638 · Cited by 1
“Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals with Type 2 diabetes mellitus (T2DM), especially in low-and middle-income countries [1, 2].”
Le, Z., Lou, Y., & Zou, Y. (2025) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2025.112469 · Cited by 1
Nyandwi, J. B., Munezero, P. C., Uwambajimana, C., Pender, G. C., Katandula, J., Umumararungu, T., Sinumvayo, J. P., Suleiman, I. E., Daba, T. M., Kagisha, V., et al. (2025) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2025.14880 · Cited by 1
QTc Interval and Its Associated Factors in Patient With Type 2 Diabetic Mellites
Sinamaw, D., Adane, T., Ashenef, B., Baylie, T., & Mekete, Y. S. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/8664620 · Cited by 1
“There is a signi fi cant connection between diabetes mellitus (DM) and cardiovascular diseases (CVDs), which is a major contributor to illness and death among diabetic patients [1 – 3].”
Cui, Y., Li, L., Li, Y., & Yu, P. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s572295 · Cited by 1
Self-citationWang, R., Dang, C., Gao, Z., Wu, D., Lian, Y., Wang, X., & Mi, S. (2025) · Foods · doi:10.3390/foods14244279 · Cited by 1
“Abnormalities of lipid metabolism are typically characterized by high levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and low levels of high-density lipoprotein cholesterol (HDL-C) [27].”
Fujimoto, T., Uchikawa, K., Akasaka, H., Yasunobe, Y., Yoshida, S., Onishi, Y., Minami, T., Asada, Y., Isaka, M., Sugimoto, K., et al. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70224 · Cited by 1
“DM is also a well-established risk factor for both renal function decline and cardiovascular disease 27 – 30 .”
Amer, O. E., Sabico, S., Alnaami, A. M., Wani, K., & Al-Daghri, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1674706 · Cited by 1
Mai, T. N., Phượng, B. T., Huyen, T. T., & Nam, N. T. (2025) · Natural Product Sciences · doi:10.20307/nps.2025.31.4.278 · Cited by 1
Liu, B., Chen, J., He, J., Xue, Q., Liu, Y., Gao, F., & Qi, H. (2026) · Biology of Sex Differences · doi:10.1186/s13293-026-00830-y · Cited by 1
“It is well-established that T2DM is linked to a higher risk of cardiovascular diseases, including carotid artery stenosis, and other vascular complications [3, 4].”
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 2
Arowolo, A., bennie, L., Werfalli, M., Johnson, R., & Engel, M. E. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03117-w · Cited by 1
Corrao, S., Orlando, V., Manno, S. B., Cangialosi, V., & Argano, C. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04281-6 · Cited by 1
Bonilha, I., Yoshinaga, M. Y., Chaves‐Filho, A. B., Gomes, É. I. L., Santos, R. S., Breder, I. S. S., Breder, J. D. S. C., Miyamoto, S., Nadruz, W., Kontush, A., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120686 · Cited by 1
Wei, B.-Y., Zuo, X., Feng, C., Shang, X., Yang, Y.-C., Zhang, R., Shi, Z., Wang, W.-T., Wu, J.-Q., Wang, H.-L., et al. (2026) · Life Science · doi:10.1016/j.lfs.2026.124368 · Cited by 1
Lu, F. M., Lim, Y. Q., Yu, Y., & Kao, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70981 · Cited by 1
TXNIP Is Positioned as a Key Mediator of Hyperglycemia-Induced Vascular Senescence
Qian, X., Chen, X., Chai, Y., Niu, Y., Ning, X., Mao, Q., Hu, Q., & Su, Q. (2026) · Diabetes · doi:10.2337/db25-1093 · Cited by 2
“Evidence suggests a close association between VSMC senescence and the pathophysiology of type 2 diabetes (18).”
Lin, J., Chen, Y., & Poon, L. C. (2026) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2026.102051 · Cited by 1
Dharmalingam, K., Sharon, J. S., & Abhoorvaa, O. C. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100479 · Cited by 1
Red blood cells in prediabetes: Early alterations, progressive trajectories, and clinical potential
Hassanein, A., & Akhtar, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113518 · Cited by 1
Petca, B.-L., Popovici, P.-A., Igna, A. D., Ghitea, T. C., & Popoviciu, M. S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187315 · Cited by 1
“Consequently, contemporary diabetes management has shifted from a glucose-centered approach toward comprehensive cardiovascular and renal risk assessment and multifactorial intervention [1–3].”
How SGLT2 inhibitors interact with metformin? A molecular dynamics study
Maleš, V. K., & Požar, M. (2023) · Molecular Simulation · doi:10.1080/08927022.2023.2196346 · Cited by 1
Tiwari, N., Saxena, S., Dadheech, S., Chaudhary, L., Saxena, M., Gautam, S. A., Jadoun, R. S., Kumar, R., Gupta, S., & Mahadik, S. S. (2023) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2023.9.1.0356 · Cited by 1
“Uncertainty persists regarding the incidence and death trends of CVD in T2DM patients in middle-and low-income countries [6].”
BackgroundAssessment of Left Ventricular Diastolic Reserve in Diabetic Patients by Stress Echocardiography
Alseenmy, A. A., Attia, W. M., Khalaf, H. A. E., & Amin, F. R. (2023) · Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · doi:10.58675/2682-339x.1721 · Cited by 1
Li, P.-I., & Guo, H. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i7.1091 · Cited by 1
González-Salvatierra, S., García-Fontana, B., Martínez-Heredia, L., Lacal, J., Andújar-Vera, F., la Torre, R. S.-D., Moratalla-Aranda, E., Alonso, S. L., García‐Fontana, C., & Muñoz‐Torres, M. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00320.2023 · Cited by 1
Singh, R. K., Singh, K. K., Singh, A., Khan, I. A., & Yadav, S. C. (2023) · Cureus · doi:10.7759/cureus.46904 · Cited by 1
Ndlovu, M., Dludla, P. V., Muvhulawa, N., Ntamo, Y., Mayeye, A., Luphondo, N., Hlengwa, N., Basson, A. K., Mabhida, S. E., Hanser, S., et al. (2023) · Diabetology · doi:10.3390/diabetology4040050 · Cited by 1
“While T2D was historically associated with older adults [16], it is now known that many diverse factors are associated with the development and progression of this condition even in children and adolescents [17,18].”
BackgroundAl‐Sofiani, M. E., ALHALEES, D. Z., Aljebreen, J. A., ABUDAHESH, J. A., BAMOGADDAM, G. S., AlBraithen, G., & Jammah, A. A. (2024) · Cureus · doi:10.7759/cureus.53844 · Cited by 1
“…failure, particularly those with reduced ejection fraction, and the consideration of GLP-1RAs for high-risk T2DM patients without established CVD. Additionally, GLP-1RAs show notable benefits in reducing major adverse cardiovascular events for T2DM patients with established atherosclerotic CVD [4].”
BackgroundZhou, E., Liang, Y., Chen, Q., Bi, J., Chen, J., Li, Y., & Li, L. (2024) · Journal of Food Biochemistry · doi:10.1155/2024/5774255 · Cited by 1
“Diabetes mellitus and its complications greatly afect patients’ quality of life and physical health [2].”
BackgroundSelf-citationAL-Sahi, M. M., AL-Hasnawi, S. M. J., & Ali, M. M. (2024) · kerbala journal of pharmaceutical sciences · doi:10.62472/kjps.v14.i23.116-124 · Cited by 1
Imam, H., Ahmed, F., Muhammad, S., Babar, B., Shah, A. A., Shah, S. D. A., & Lashari, M. N. (2024) · Ukrainian journal of cardiovascular surgery · doi:10.30702/ujcvs/24.32(02)/ia020-4550 · Cited by 1
Sarabi, N., Moosavi, A., Karimi, H., & Moradi, E. (2024) · طلوع بهداشت یزد · doi:10.18502/tbj.v23i2.16096 · Cited by 1
Aslam, M. R., Perala, A., Wishart, A. V., Hamouda, R. K., Elsaady, E., & Khan, S. (2024) · Cureus · doi:10.7759/cureus.70642 · Cited by 1
“It can cause complications such as diabetic nephropathy, neuropathy, and retinopathy, and there is also an increased risk of having cardiovascular diseases [4] and cancer [5].”
BackgroundBian, L., Qiu, M., Li, J., Zhang, L., Hunt, P. R., Kuster, M., & Han, Y. (2024) · Cardiology Discovery · doi:10.1097/cd9.0000000000000133 · Cited by 1
Role of Yoga in Modulating Vascular Aging in Type 2 Diabetes Mellitus
Warad, V. G., Kankanala, A. R., Kadagud, A. M., & Khodnapur, J. P. (2024) · Cureus · doi:10.7759/cureus.72507 · Cited by 1
Xie, Y., Fan, Y., Liu, X., Li, Z., & Liu, S. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119012 · Cited by 1
Probiotics to Prevent Lifestyle and Metabolic Diseases
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_10 · Cited by 1
Metadata
- Authors
- Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B.
- Venue
- Cardiovascular Diabetology
- Published
- 2022-05-14
- Volume
- 21
- Issue
- 1
- Pages
- 74-74
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC9107726
- OpenAlex
- W4280586315
- Cited by
- 464
- References
- 137
- Citations by year
- 2026: 97 · 2025: 153 · 2024: 137 · 2023: 69 · 2022: 8
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- the Lanzhou Chengguan District Science and Technology Plan Project (2021-9-19)
- the hospital fund of the First Hospital of Lanzhou University (ldyyyn2020-93)
- the Construction Program of Gansu Provincial Clinical Medical Research Center for Endocrine Diseases (20JR10FA667)
- the Special Funds of Science and Technology Development of the Chinese Central Government to guide Local (1004TCYA032)
- the Gansu Provincial Natural Science Foundation (20JR10RA681)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, personalized medicine, cardiovascular risk management, glycemic control, blood pressure control, lipid-lowering therapy, glucose-lowering agents, antiplatelet therapy, cardiovascular disease prevention, low- and middle-income countries
- MeSH terms
- Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Lipids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
